Rilpivirine

A simple, Accurate, precise method was developed for the simultaneous estimation of the Rilpivirine and Cabotegravir in dosage form. Chromatogram was run through AgilentC18 150 x 4.6mm, 5.0mm.1 Mobile phase containing Buffer 0.1% Ammonium Acetate: Acetonitrile taken in the ratio 55:45v/v was pumped through the column at a flow rate of 1.0 ml/min. Temperature was maintained at 30°C. The optimized wavelength selected was 260 nm. The retention time of Rilpivirine and Cabotegravir was found to be 2.238 min and 2.953 min. %RSD of the Rilpivirine and Cabotegravir was found to be 0.5 and 0.5 respectively. %Recovery was obtained as 99.85% and 99.84% for Rilpivirine and Cabotegravir respectively. LOD and LOQ values obtained from regression equations of Rilpivirine and Cabotegravir were 0.11, 0.3,2, and 0.02, 0.06 respectively.2 The regression equation of Rilpivirine is y = 17712x + 2324.3 and y = 17293x + 1410.5 of Cabotegravir Retention times were decreased and that run time was decreased, so the method developed was simple and economical that can be adopted in regular Quality control test in Industries.  

In the present study a simple isocratic reverse phase HPLC method was developed for the estimation of rilpivirine in pharmaceutical formulation. The separation was carried out using a column of Zorbax Eclipse XDB-C18, 250x4.6mmi.d with 5micron particle size. The mobile phase comprises of 0.03M di potassium hydrogen orthophosphate with pH adjusted to 2.5 using dilute ortho-phosphoric acid (mobile phase solvent-A) and acetonitrile (mobile phase solvent-B) in the ratio of 15: 85 (v/v).The flow rate was 1.0 ml/min and the effluents were monitored at 284 nm. The retention time was 7.19 min. The detector response was linear in the concentration range of 100-300µg/ml. The respective linear regression equation being Y= 28817.742X-14741.2. The limit of detection (LOD) and limit of quantification (LOQ) for rilpivirine were found to be 0.05µg/ml and 0.15 µg/ml respectively. The assay was found to be 99.85%.The method was validated by determining its accuracy, precision and system suitability. The results of the study showed that the proposed RP-HPLC method is simple, rapid, precise and accurate, which is useful for the routine determination of rilpivirine in its pharmaceutical dosage form.

Aim of present study was to develop self emulsifying drug delivery system (SEDDS) for enhancement of solubility, dissolution rate and oral bioavailability of model drug Rilpivirine. Fifteen formulations were prepared using different oils, surfactants and co-surfactants. A pseudo ternary phase diagram was constructed to identify the self-micro emulsification region. Further, the resultant formulations were investigated for clarity, phase separation, drug content, % transmittance, globule size, freeze-thaw stability and in vitro dissolution studies. On the basis of dissolution profile and other above mentioned studies, F5 was found to be the best formulation of Rilpivirine SEDDS which contains Captex 355(Oil), Kolliphor RH 40 (Surfactant) and PG (Co-surfactant). In vivo studies revealed that the oral bioavailability of Rilpivirine from SEDDS was 2.2-fold higher compared to that of pure Rilpivirine suspension in rats, suggesting a significant increase (p